Duality Advisers LP Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Duality Advisers LP boosted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 56.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,763 shares of the biopharmaceutical company’s stock after buying an additional 9,619 shares during the quarter. Duality Advisers LP’s holdings in Amicus Therapeutics were worth $380,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Amicus Therapeutics by 0.4% during the third quarter. Vanguard Group Inc. now owns 27,131,873 shares of the biopharmaceutical company’s stock valued at $329,924,000 after purchasing an additional 107,456 shares during the period. William Blair Investment Management LLC boosted its stake in shares of Amicus Therapeutics by 349.9% during the third quarter. William Blair Investment Management LLC now owns 10,376,763 shares of the biopharmaceutical company’s stock valued at $126,181,000 after purchasing an additional 8,070,098 shares during the period. Fiera Capital Corp boosted its stake in shares of Amicus Therapeutics by 2.1% during the third quarter. Fiera Capital Corp now owns 5,085,871 shares of the biopharmaceutical company’s stock valued at $61,844,000 after purchasing an additional 106,086 shares during the period. American Century Companies Inc. boosted its stake in shares of Amicus Therapeutics by 11.0% during the third quarter. American Century Companies Inc. now owns 4,343,870 shares of the biopharmaceutical company’s stock valued at $52,821,000 after purchasing an additional 429,257 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in Amicus Therapeutics by 392.4% in the third quarter. Victory Capital Management Inc. now owns 2,949,206 shares of the biopharmaceutical company’s stock worth $35,862,000 after acquiring an additional 2,350,262 shares during the period.

Amicus Therapeutics Stock Performance

FOLD opened at $10.17 on Friday. Amicus Therapeutics, Inc. has a 52-week low of $9.70 and a 52-week high of $14.57. The company has a debt-to-equity ratio of 2.42, a quick ratio of 2.52 and a current ratio of 2.88. The firm’s 50-day moving average price is $12.02 and its 200-day moving average price is $12.00.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. The company had revenue of $115.08 million for the quarter, compared to analyst estimates of $115.11 million. Analysts predict that Amicus Therapeutics, Inc. will post 0.01 earnings per share for the current year.

Insider Activity

In other news, insider David Michael Clark sold 4,427 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.00, for a total transaction of $61,978.00. Following the transaction, the insider now owns 253,664 shares in the company, valued at $3,551,296. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, insider David Michael Clark sold 4,427 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $14.00, for a total value of $61,978.00. Following the sale, the insider now owns 253,664 shares in the company, valued at $3,551,296. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Bradley L. Campbell sold 4,167 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $14.00, for a total value of $58,338.00. Following the completion of the sale, the chief executive officer now owns 871,219 shares in the company, valued at approximately $12,197,066. The disclosure for this sale can be found here. Insiders have sold a total of 48,108 shares of company stock worth $662,605 over the last 90 days. 2.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on FOLD. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $22.00 price objective on shares of Amicus Therapeutics in a research note on Thursday, February 29th. JPMorgan Chase & Co. reduced their target price on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Monday, March 18th.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.